These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 8926945

  • 1. [Tamoxifen: modern drug therapy of estrogen-dependent breast tumors].
    Jovanović-Mićić D, Beleslin DB, Nikolić SS.
    Med Pregl; 1996; 49(7-8):287-90. PubMed ID: 8926945
    [Abstract] [Full Text] [Related]

  • 2. Estrogen dependent growth inhibitory effects of tamoxifen but not genistein in solid tumors derived from estrogen receptor positive (ER+) primary breast carcinoma MCF7: single agent and novel combined treatment approaches.
    Nobert GS, Kraak MM, Crawford S.
    Bull Cancer; 2006 Jul; 93(7):E59-66. PubMed ID: 16873071
    [Abstract] [Full Text] [Related]

  • 3. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M, Kodama T.
    In Vivo; 2001 Jul; 15(4):319-25. PubMed ID: 11695224
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].
    Semilgazov VF, Manikhas AG, Semiglazov VV, Bozhok AA, Dashian GA, Ivanov VG, Paltuev RM, Vasil'ev AG, Shchedrin DE, Ermachenkova AM, Nikitina IV, Pen'kov KD, Bessonov AA, Tabagua TT, Kolar'kova VV.
    Vopr Onkol; 2011 Jul; 57(5):567-77. PubMed ID: 22238925
    [No Abstract] [Full Text] [Related]

  • 6. The efficacy of tamoxifen in estrogen receptor-positive breast cancer cells is enhanced by a medical nutriment.
    Marcsek Z, Kocsis Z, Jakab M, Szende B, Tompa A.
    Cancer Biother Radiopharm; 2004 Dec; 19(6):746-53. PubMed ID: 15665622
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 10. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE.
    Cancer; 2004 Sep 15; 101(6):1311-22. PubMed ID: 15368322
    [Abstract] [Full Text] [Related]

  • 11. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
    Breast Cancer Res; 2008 Sep 15; 10(5):R88. PubMed ID: 18928543
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
    Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM.
    Clin Cancer Res; 2004 Sep 01; 10(17):5670-6. PubMed ID: 15355892
    [Abstract] [Full Text] [Related]

  • 14. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR, Boeddinghaus IM, Riddler S, Haynes BP, Hardcastle IR, Rowlands M, Grimshaw R, Jarman M, Dowsett M.
    Cancer Res; 1999 Aug 01; 59(15):3646-51. PubMed ID: 10446976
    [Abstract] [Full Text] [Related]

  • 15. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
    Sgroi DC, Haber DA, Ryan PD, Ma XJ, Erlander MG.
    Cancer Cell; 2004 Nov 01; 6(5):445. PubMed ID: 15542428
    [No Abstract] [Full Text] [Related]

  • 16. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
    Younus J, Vandenberg TA.
    Bull Cancer; 2005 Apr 01; 92(4):E39-44. PubMed ID: 15888383
    [Abstract] [Full Text] [Related]

  • 17. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR.
    Clin Cancer Res; 2001 Dec 01; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [Abstract] [Full Text] [Related]

  • 18. Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer.
    Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY.
    Oncol Rep; 2003 Dec 01; 10(1):141-4. PubMed ID: 12469160
    [Abstract] [Full Text] [Related]

  • 19. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC, Johnston SR, Smith IE, Dowsett M.
    Clin Cancer Res; 1997 Sep 01; 3(9):1643-51. PubMed ID: 9815855
    [Abstract] [Full Text] [Related]

  • 20. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB, Feuer EJ, Harlan LC, Abrams J.
    J Natl Cancer Inst Monogr; 2006 Sep 01; (36):7-15. PubMed ID: 17032888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.